<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002702</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064500</org_study_id>
    <secondary_id>CNR-9506</secondary_id>
    <secondary_id>EU-95024</secondary_id>
    <nct_id>NCT00002702</nct_id>
  </id_info>
  <brief_title>Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx</brief_title>
  <official_title>Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells of&#xD;
      the mouth or oropharynx. Radiation therapy uses high-energy x-rays to damage tumor cells. It&#xD;
      is not known whether giving interleukin-2 with surgery and radiation therapy is more&#xD;
      effective than surgery and radiation therapy alone.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying surgery and radiation therapy alone to&#xD;
      see how well they work compared to surgery, radiation therapy, and interleukin-2 in treating&#xD;
      patients with cancer of the mouth or oropharynx.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the disease-free and overall survival in patients with previously untreated&#xD;
           squamous cell carcinoma of the oral cavity or oropharynx treated with resection with or&#xD;
           without and neoadjuvant and adjuvant perilymphatic interleukin-2 (IL-2) and&#xD;
           radiotherapy.&#xD;
&#xD;
        -  Compare the response rate in patients treated with these regimens.&#xD;
&#xD;
        -  Determine the local and systemic effects of locoregional IL-2 on host-tumor interaction&#xD;
           and immune properties in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center&#xD;
      and tumor stage (T2, N0-2 vs T2, N3 or T3-4, N0-3). Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo induction comprising interleukin-2 (IL-2) via perilymphatic&#xD;
           injections to the ipsilateral myelohyoid muscle and insertion of the sternocleidomastoid&#xD;
           muscle on days 1-5 and 8-12. Within 10 days after the last IL-2 injection, patients&#xD;
           undergo en bloc resection of the primary tumor and corresponding lymphatic drainage area&#xD;
           and pre-study margins. Beginning within 4 weeks after surgery, patients with T2, N0-3&#xD;
           disease but with pathohistological evidence of node invasion or capsular rupture of node&#xD;
           metastasis or T3-4, N0-3 disease undergo adjuvant radiotherapy 5 days a week for 4.5-6.5&#xD;
           weeks. Beginning within 4 weeks after surgery or radiotherapy (if applicable), patients&#xD;
           receive adjuvant IL-2 via perilymphatic injections to the contralateral myelohyoid&#xD;
           muscle and insertion of the sternocleidomastoid muscle on days 1-5. Adjuvant IL-2&#xD;
           continues monthly for at least 1 year in the absence of disease progression.&#xD;
&#xD;
        -  Arm II: Patients undergo resection and radiotherapy (if eligible) as in arm I. Patients&#xD;
           are followed monthly for 1 year and then every 2 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 260 patients (130 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 1992</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival at 3 and 5 years</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence/metastasis rate at 3 and 5 years</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Local and systemic effects of treatment</measure>
  </primary_outcome>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven squamous cell carcinoma of the oral cavity or oropharynx&#xD;
&#xD;
               -  Operable, primary, unilateral, stage T2-4, N0-3, M0 disease&#xD;
&#xD;
               -  No high probability of bilateral lymphatic spread (requirement for bilateral neck&#xD;
                  dissection)&#xD;
&#xD;
          -  No tumor involvement of the following sites:&#xD;
&#xD;
               -  Pterygopalatine fossa&#xD;
&#xD;
               -  Carotid artery&#xD;
&#xD;
               -  Maxillary sinus&#xD;
&#xD;
               -  Facial skin&#xD;
&#xD;
               -  Anterior floor of the mouth&#xD;
&#xD;
               -  Base of the tongue infiltrating more than 1 cm&#xD;
&#xD;
          -  Measurable or evaluable disease by physical exam and/or noninvasive imaging&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  75 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000/mm3&#xD;
&#xD;
          -  Platelet count at least 60,000/mm3&#xD;
&#xD;
          -  Hematocrit at least 30%&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No coronary artery disease&#xD;
&#xD;
          -  No serious arrhythmia&#xD;
&#xD;
          -  No evidence of prior myocardial infarction on ECG (stress test required if in doubt)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No autoimmune disease&#xD;
&#xD;
          -  No contraindications to pressor agents&#xD;
&#xD;
          -  No serious infection requiring antibiotics&#xD;
&#xD;
          -  No other concurrent primary malignancy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior or other concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior or concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No prior or concurrent hormonal therapy&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior major organ allografts&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior therapy&#xD;
&#xD;
          -  No other concurrent investigational drugs, agents, or devices&#xD;
&#xD;
          -  No concurrent nonsteroidal antiinflammatory drugs, ranitidine, cimetidine, or coumarin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giorgio Cortesina, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universita Degli Studi di Turin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universita Degli Studi di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. Cervellera, MD</last_name>
      <phone>39-080-5478-660</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cattedra di Oncologia Medica - Universita degli Studi di Cagliari</name>
      <address>
        <city>Cagliari</city>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. Puxeddu, MD</last_name>
      <phone>39-070-5109-6253</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C. Calearo, MD</last_name>
      <phone>39-0532-209-296</phone>
      <email>ccv@dns.unife.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi di Florence - Policlinico di Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>O. Fini-Storchi, MD</last_name>
      <phone>39-55-411739</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universita di Torino</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. Valente, MD</last_name>
      <phone>39-011-670-5955</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedaliera Ordine Mauriziano</name>
      <address>
        <city>Turin</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. Forni, MD</last_name>
      <phone>39-11-508-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C. Curioni, MD</last_name>
      <phone>39-444-993-906</phone>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>stage II squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage II squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

